


Dear Healthcare provider,
We would like to invite you to attend the Meeting titled
**Vaccination for the prevention of
shingles disease**

Riyadh



TO A HEALTHIER LIFE

REGISTER HERE

SPEAKERS



Dr. Hawra AlBayat

Internist and Infectious diseases Consultant
MBBS, Saudi board program of Internal medicine and Saudi
fellowship of infectious diseases program, working in King
Saud medical city in Riyadh, working in HIV centre



Dr. Raneem Milyani

Consultant Geriatric Medicine at King Saud Medical City,
National Guard Hospital Riyadh, Saudi, head of scientific
committee and a board member of the Saudi Geriatrics
Society.



Dr. Fayssal Farahat

Consultant and Director of Community and PublicHealth at
the Infection Prevention and Control Program, Ministry of
National Guard Health Affairs, Riyadh, Saudi Arabia.



Prof. Lars Rombo

Professor, Department of Medical Biochemistry and
Microbiology, Zoonosis Science Center, Uppsala University,
Uppsala, Sweden
Consultant, Dept infectious diseases Mälarsjukhuset
Eskilstuna.
He has extensive experience in (successful) vaccine trials
since 1998



Dr. Youness Lagoubi

Medical Doctor, with Health Technology Assessment and
Marketing degrees. Currently working as a Global Senior
Medical Manager- Shingrix.
He has authored various publications and continues to
contribute to various Scientific Congresses & Symposium as
a Speaker.

AGENDA

Riyadh, Friday 20 May

Time: 02:00 – 04:30 PM

Topic	Speaker	Duration
Opening	Dr. Raneem Meliani	02:00 - 02:15 PM
Paving the way to a Healthy Aging Community	Dr. Faysal Farahat	02:15 - 02:45 PM
Shingles Disease Prevention: a nation's new priority	Dr. Hawra AlBayat	02:45 - 03:15 PM
Crafting the innovative recombinant and adjuvanted Recombinant Zoster Vaccine	Dr. Youness Lagoubi	03:15 - 03:45 PM
Recombinant Zoster Vaccine efficacy and safety: highlights from Important studies.	Prof. Lars Rombo	03:45 - 04:15 PM
Q&A	Dr. Raneem Meliani	04:15 - 04: 30 PM

Registration is mandatory for this event

REGISTER HERE

For Shingrix PI Please [Click here](#)

For more information, please refer to the prescribing information or contact GlaxoSmithKline
viagcc.medinfo@gsk.com.

To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com.
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via
Gulf-KSA.Product-Complaints@gsk.com.

This email is intended for Saudi Arabia healthcare professionals only. You are receiving this email as we have your details as a health care professional. If you do not wish to receive these emails in future or unsubscribe, E-mail programs can consider these messages as junk mail and may automatically put them in your bulk or junk folder. To ensure the e-mails you've requested are delivered to your inbox, add our e-mail address to your address book. Please do not reply to this message. These emails are not monitored and do not accept replies. About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you, and how we use your information, [click here](#). You can also view our [terms of use](#).

